DADC
CASC

D.A. Davidson & Co’s Cascadian Therapeutics, Inc. CASC Stock Holding History

D.A. Davidson & Co’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-3,833
Closed -$14K – 2315
2017
Q2 		$14K Sell
3,833
-2,900
-43% -$11.5K ﹤0.01% 1943
2017
Q1 		$27K Buy
6,733
+1,035
+18% +$4.35K ﹤0.01% 1748
2016
Q4 		$24K Buy
5,698
+331
+6% +$2.14K ﹤0.01% 1875
2016
Q3 		$52K Buy
5,367
+200
+4% +$1.42K ﹤0.01% 1513
2016
Q2 		$29K Buy
5,167
+1,430
+38% +$9.71K ﹤0.01% 1632
2016
Q1 		$28K Hold
3,737
– – ﹤0.01% 1608
2015
Q4 		$49K Sell
3,737
-19,439
-84% -$335K ﹤0.01% 1400
2015
Q3 		$381K Sell
23,176
-1,343
-5% -$27.5K 0.01% 618
2015
Q2 		$550K Buy
+24,519
New +$388K 0.02% 547

Other funds holding CASC

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
SH
Sandia Holdings Greenwich, Connecticut $213M AUM 29.35% 1-Year Est. Return

D.A. Davidson & Co's CASC Position: Q3 2017 in Review

D.A. Davidson & Co sold out of Cascadian Therapeutics, Inc. (CASC) in Q3 2017, closing a stake of 3,833 shares — an estimated $14K sold.

D.A. Davidson & Co first reported a position in CASC in Q2 2015 and held it in 9 quarters. The position peaked at $550K in Q2 2015. 79 funds tracked by Wall St. Rank hold CASC as of Q3 2017.

  • D.A. Davidson & Co reported no remaining Cascadian Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • D.A. Davidson & Co sold 3,833 Cascadian Therapeutics, Inc. shares in Q3 2017, an estimated $14K.
  • D.A. Davidson & Co first reported a position in Cascadian Therapeutics, Inc. in Q2 2015 and held it in 9 quarters.
  • D.A. Davidson & Co's Cascadian Therapeutics, Inc. position peaked at $550K in Q2 2015.
  • 79 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q3 2017.

Based on D.A. Davidson & Co's 13F filing for Q3 2017, filed 8 Nov 2017.